READING, Pa., Jan. 10, 2019 /PRNewswire/ — Recent reports published by PharmaForce International (PFI) provide 2018 competitive benchmarking data of leading pharmaceutical companies’ strategies for leveraging the field medical function in Europe. The reports profile ten companies within each of the five European countries – France, Germany, Italy, Spain, and the United Kingdom.
Since the previous studies were published in 2015, there has been a rise in the presence of MSLs across multiple therapeutic areas. The majority of the therapeutic areas in these studies have shown visible growth in MSL deployment, but Vaccines, Gastrointestinal, and Oncology/Hematology spaces have shown the largest expansions in all five countries.
Joyce Wedemeyer, Director of Marketing and Sales at PharmaForce International, says that pharmaceutical companies are recognizing the strategic importance of leveraging the function of Medical Science Liaisons and their versatile roles.
"MSLs hold a valuable position in forming quality relationships with Key Opinion Leaders and communicating scientific expertise for assigned brands or therapy areas," says Wedemeyer.
Additional MSL trends captured in these reports include insight specific to:
- Strategic approach to the MSL function
- Size and structure of MSL forces
- Reporting structure
- FTEs by therapeutic category as defined by PharmaForce International
- Key role of personnel
- KOL assignment allocations by type
- Qualifications by title
- Compensation of MSL personnel
- Performance evaluation metrics
For more information on the reports mentioned above, please contact Joyce Wedemeyer at Joyce.Wedemeyer@strategicreports.com or by phone at 610-370-2906.
PharmaForce International (PFI) is a competitive intelligence firm with over two decades of experience in the pharmaceutical and biotech industries. PFI has become the market leader in commercial operations benchmarking and competitive intelligence. The globally focused company employs market place experts uniquely qualified to perform research required by clients in most major pharmaceutical markets around the world.
SOURCE PharmaForce International